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Retinitis pigmentosa 2 (RP2) is the causative gene for a form of X-linked retinal 
degeneration. RP2 was previously shown to have GAP activity towards the small 
GTPase ARL3 via its N-terminus, but the function of the C-terminus remains elusive. 
Here, we report a novel interaction between RP2 and Osteoclast-stimulating factor 1 
(OSTF1), an intracellular protein that indirectly enhances osteoclast formation and 
activity and is a negative regulator of cell motility. Moreover, this interaction is 
abolished by a human pathogenic mutation in RP2. We utilized a structure-based 
approach to pinpoint the binding interface to a strictly conserved cluster of residues 
on the surface of RP2 that spans both the C- and N- terminal domains of the protein, 
and which is structurally distinct from the ARL3 binding site. In addition, we show 
that RP2 is a positive regulator of cell motility in vitro, recruiting OSTF1 to the cell 
membrane and preventing its interaction with the migration regulator Myo1E.  
 
Introduction 
Retinitis pigmentosa 2 (RP2) is mutated in 7-18% of patients suffering from X-linked 
Retinitis pigmentosa (XLRP), a severe and untreatable form of progressive retinal 
degeneration. RP collectively represents a heterogeneous group of retinal 
degenerative disorders marked by photoreceptor loss and is a leading cause of 
inherited blindness affecting 1:3000-1:7000 people worldwide1,2. RP2 is a 350-
residue protein whose expression at the protein level is not restricted to the retina 
but is also expressed in a wide range of tissues including the brain and the kidney 
(Proteomics database, https://www.proteomicsdb.org). Structurally, RP2 
encompasses two distinct domains which appear to serve distinct roles3. The N-
terminal β-helix domain is homologous to Tubulin Cofactor C (TBCC), and the C-
terminal ferredoxin α/β domain displays similarity to Nucleoside Diphosphate 
Kinases (NDPK)3. RP2 is predominantly targeted to the plasma membrane due to 
dual acylation of its N-terminus4,5; this subcellular localization of RP2 is important for 
its function and is pathologically relevant6. Notably, RP2 is also associated to 
primary cilia and the specialized connecting cilia of the photoreceptors, both in terms 

























While several proteins have been reported to interact with RP2, the most well-
characterized interaction partner is ARL3, a small GTPase with suggested roles in 
the intracellular trafficking of ciliary proteins10-13, loss of which leads to photoreceptor 
degeneration and renal ciliopathy in mice14,15. We previously revealed the crystal 
structure of RP2 coupled to ARL3, demonstrating that the interaction of the two 
proteins is mediated exclusively by the N-terminal domain of RP2 and that RP2 
displays GTPase-activating protein (GAP) activity against ARL3, stimulating its GTP 
hydrolysis by several orders of magnitude16. 
The disruption of the RP2-ARL3 complex is clearly a major contributor to the 
development of retinal degeneration, not only because the ARL3 binding interface on 
RP2 is a mutational hotspot17, but also because an ARL3 mutation was recently 
described to cause autosomal dominant RP18. The most well-characterized function 
of the complex is in intracellular trafficking pathways for lipid-modified retinal and 
general ciliary proteins. In particular, structural and biochemical studies have proven 
the ability of GTP-bound ARL3 to allosterically displace protein cargo from 
chaperones PDE6δ and UNC119, which bind and solubilize lipid-modified 
membrane-anchored proteins such as NPHP3 and Rheb12,13. Animal model studies 
have linked this function of ARL3 with the correct targeting of lipid-modified 
phototransduction proteins, such as the prenylated PDE6 holoenzyme, rhodopsin 
kinase GRK1 and acylated transducin Tα, to the photoreceptor connecting cilium15. It 
is therefore believed that RP2 has a role in the regulation of intracellular shuttling of 
those proteins, via its ability to stimulate ARL3 GTP hydrolysis19. ARL13B, mutated 
in Joubert’s syndrome, was recently identified as a GEF for ARL3, completing the 
cycle of GTPase regulation by stimulating GDP to GTP exchange9. It is believed that 
a gradient of ARL3 GTP- and GDP- bound forms is created in ciliated cells due to 
the combination of ARL13B’s exclusive localization inside the ciliary axoneme and 
RP2’s presence at the basal body, which ensures release of lipid-modified cargo 
within the correct locations9.  
However, other studies report different phenotypes associated with RP2 loss that 
might be independent of its function in this pathway, such as global post-Golgi 
























ARL3 was recently described as an interaction partner of STAT3, suggesting a new 
role for RP2 in the regulation of transcription21.  
Fundamental questions remain unanswered in the field. For example, given the wide 
tissue distribution of RP2, it is reasonable to ask whether RP2’s function is restricted 
to the photoreceptor connecting cilia and primary cilia or if it has other functions 
elsewhere. Furthermore, while the function of the N-terminal, TBCC-like domain of 
RP2 has been well characterised as the binding interface for the interaction with 
ARL3 and the catalytic centre of the protein, the C-terminus has been poorly 
characterised with no currently known function. It is known that although it shares 
weak sequence homology with NDPK, the C-terminal domain of RP2 does not 
possess kinase activity as key catalytic residues are not conserved3. Apart from a 
report attributing DNA binding and exonuclease activity to this domain22, and another 
report that it contributes to the overall protein stability17, it has been generally 
assumed, without any experimental evidence, that the domain participates in protein-
protein interactions3. In this study, we report a novel interaction between RP2 and 
OSTF1, a 214-residue protein that was initially identified in a screen for molecules 
whose overexpression leads to the secretion of factors that indirectly stimulate 
osteoclast maturation and bone resorption in culture23. Expression of OSTF1 at 
mRNA and protein level has been detected in several human tissues including the 
retina23 (Proteomics database, https://www.proteomicsdb.org). The exact function of 
this molecule is yet unknown, but it has been suggested to be an adaptor for c-Src’s 
function in the actin cytoskeleton24. It was also recently identified as a negative 
regulator of cell motility in cancer cell lines, under control of the ERK1/2 pathway25. 
OSTF1 exerts this effect by acting as a cytoplasmic anchor for long-tailed type 1 
Myosin, Myo1E, preventing it from localizing to sites of actin nucleation in 
lamellipodia25,26. We conducted structural and biochemical analyses to characterize 
the RP2-OSTF1 interaction and show that the interaction interface on RP2 does not 
overlap with the ARL3 binding interface and that the formation of a trimeric RP2-
OSTF1-ARL3 complex is possible. In addition, we show that the OSTF1 binding 
interface spans both the C- and N- terminal domains of the protein and that the 
residues that participate in the interaction belong to a surface “patch” on RP2 that 
displays remarkable conservation status among vertebrates, arguing for major 
























regulator of OSTF1’s ability to influence cell motility, via modulating the availability of 
OSTF1 to interact with Myo1E.   
 
Results 
OSTF1 is a novel interaction partner of RP2 
To look for novel RP2 functions through the identification of novel interaction partners, 
we conducted a yeast two-hybrid screen by using human full-length RP2 as the bait 
protein. Of 91 clones, 41 encoded full-length OSTF1 (Figure 1a). Direct interaction 
between OSTF1 and RP2 was confirmed in two directions in a targeted yeast two-
hybrid assay (Figure 1b). OSTF1 is a 214-residue protein consisting of an N-terminal 
proline-rich region, a Src-homology 3 domain (SH3), 4 ankyrin repeats (ANK) and a 
well-conserved acidic amino acid cluster at the C-terminus. Coimmunoprecipitation 
(co-IP) confirmed the interaction between exogenously expressed OSTF1 and RP2 in 
HEK293T cells (Figure 1c). In addition, the interaction was confirmed by reciprocal 
pulldown analyses in bovine retinal extracts using recombinant GST-RP2 or GST-
OSTF1 as bait proteins (Figure 1d). To determine the thermodynamic parameters of 
the RP2-OSTF1 interaction in solution, we conducted isothermal titration calorimetry 
(ITC) using full-length RP2 and full-length His-tagged OSTF1 (Figure 1e). ITC analysis 
showed robust complex formation with 1:1 stoichiometry; the equilibrium association 
constant of the interaction was derived as 5.28 µM and the reaction is exothermic with 
an enthalpic contribution of ~7.473 kcal/mol. Moreover, indirect fluorescence 
polarisation experiments in which an equimolar complex of fluorescently labelled small 
GTPase ARL3-mantGppNHp (a non-hydrolysable GTP analog) with RP2 was titrated 
with increasing amounts of full-length (OSTF1FL) showed an affinity of OSTF1FL to 
RP2 of 0.672 µM (Supplementary table 1). 
 
OSTF1 binding does not affect the interaction of RP2 with ARL3 or its GAP 
activity 
In order to investigate if OSTF1 acts as a regulator of RP2 activity, we used 
fluorescence polarization (FP) analysis to assess if OSTF1 modulates the binding 
affinity of RP2 to ARL3 or its catalytic activity in vitro. For this purpose, we used full-
























fluorescently labelled with mantGppNHp (a non-hydrolysable GTP analog). RP2 was 
previously shown by us16 to bind to ARL3-mantGppNHp and ARL3-mantGDP/AlFx 
with higher affinity than to ARL3-mantGDP (Supplementary table 1). An increase in 
FP signal of ARL3-mantGppNHp is observed upon addition of RP2 followed by a 
further increase upon addition of OSTF1 (Figure 2a). As OSTF1 does not bind 
directly to either ARL3-mantGDP or ARL3-mantGppNHp (Figure 2b), we assume 
that OSTF1 and ARL3 can bind simultaneously on RP2 to form a trimeric complex.  
The affinity of RP2 to ARL3-mantGppNHp did not change depending on the absence 
and presence of saturating concentrations of OSTF1 (Supplementary table 1). 
Therefore, OSTF1 does not inhibit or compromise the RP2-ARL3 complex formation 
and might also be functionally independent. Moreover, a stable quadruple complex 
seems to be able to be formed with the ARL3 effector, UNC119a (Supplementary 
figure 1).  
We next investigated if the presence of OSTF1 affects the stimulation of ARL3 GTP 
hydrolysis by catalytic concentrations of RP2 in a charcoal assay. ARL3 was loaded 
with radioactively labelled 32P GTP. The GAP activity was monitored by hydrolysis 
and release of 32P leading to an increase in the radioactive signal, as described 
before16. We found that OSTF1 does not influence the intrinsic GTP hydrolysis rate 
of ARL3 or the GAP activity of RP2 (Figure 2c).  
 
The N-terminal domain of RP2 and both the SH3 and ANK domains of OSTF1 
participate in the interaction 
Since OSTF1 does not compete with ARL3 for binding to RP2, we next asked whether 
it binds exclusively to the C-terminal NDPK-like domain of RP2. To conduct this 
domain analysis of the RP2-OSTF1 interaction, we used RP2 and OSTF1 deletion 
constructs (Figure 3a) in analytical gel filtration experiments. First, we confirmed that 
full-length RP2 and OSTF1-His complex formation can be detected with this method, 
since the complex, being larger, elutes from the stationary phase earlier than the 
monomeric proteins (Figure 3b, left). Next, we repeated the assay using an N-terminal 
deletion construct of RP2 (RP2 ΔN, residues 230-350) and showed that the C-terminal 
domain alone cannot form a complex with OSTF1 (Figure 3b, right). However, deletion 
























the interaction with ARL316) does not affect complex formation (Supplementary figure 
2). Subsequently, we tested the binding of RP2 to OSTF1 deletion constructs (Figure 
3c). Interestingly, deletion of amino acids 1-74 comprising the SH3 domain of OSTF1 
(OSTF1 ΔΝ), as well as deletion of amino acids 74-214, the ANK repeats domain 
(OSTF1 ΔC), both abolish complex formation, showing that both SH3 and ANK 
domains of OSTF1 take part in the interaction (Figure 3c). This was further confirmed 
by pulldown assays from HEK293T cell lysates using GST-tagged OSTF1 constructs 
as bait (Figure 3d). While the ΔC OSTF1 construct cannot form a complex with RP2, 
it can still pulldown endogenous c-Cbl, in accordance with previous studies24.  
 
The RP2-OSTF1 interaction interface spans both domains of RP2 and is strictly 
conserved among vertebrates  
Although most RP2 mutations found in patients likely lead to null alleles due to 
severely compromised or absent RP2 expression, caused by either mRNA 
degradation or destabilized protein structure, missense mutations have been 
reported which do not affect the expression and overall stability of RP2, according to 
biochemical studies, in silico predictions or circular dichroism spectroscopy3,16,17. 
Among them, R118H and E138G are known to severely impact the RP2-ARL3 
interaction and thus affect the GAP activity of RP216. G2A and C3S mutations lead to 
altered RP2 localization by impairing dual acylation at its extreme N-terminus4. It is 
apparent that pathogenic missense RP2 mutations that are predicted to be non-
destabilizing often occur on important residues that mediate critical interactions or 
modifications and, therefore, can be particularly informative about the function of the 
protein. An exception might be R282W which has been suggested to be a low-
frequency polymorphism even though it has been identified in RP patients27,28. 
In order to assess the importance of the RP2-OSTF1 interaction for the function of 
RP2, we tested the effect of six of these mutations (G2A, C3S, R118H, E138G, 
R211L, R282W) on the interaction. We conducted GST pulldown analyses using 
recombinant full-length GST-OSTF1 as bait in lysates of HEK293T cells expressing 
either wild-type or mutant RP2 with a V5 tag and identified R211L as a mutation that 
completely abolishes the RP2-OSTF1 interaction (Figure 4a). Interestingly, R211 is 
























region. Upon multiple sequence alignment of human RP2 with a range of divergent 
orthologues (from 38% identity with the choanoflagellate Salpingoeca to 94% identity 
with Mole rat), it is apparent that the R211 position is strictly conserved among 
vertebrates, but not entirely conserved among non-vertebrate chordates and non-
chordates (Figure 4b). Hence, for the subsequent conservation analyses, only the 
vertebrate subphylum was used.   
Because R211 lies away from the ARL3 interaction interface on the opposite face of 
the GAP-domain, we hypothesized that this area of the protein along the C-terminal 
NDPK-like domain might form the binding interface for the RP2-OSTF1 interaction. 
To test this, we mapped the binding interface on the surface of RP2 using a targeted 
RP2 structure-guided mutagenesis approach and testing the effect of missense 
mutations on the OSTF1 binding. Residues to be mutated were based on a 
comprehensive in silico analysis of the conservation status among vertebrates, the 
surface properties, the proximity of the residues to R211 as well as the potential of 
post-translational modifications (Figure 4c, d). Electrostatic properties and 
hydrophobicity of residues were taken into account when choosing which residues to 
mutate, as highly charged and/or exposed hydrophobic amino acids often participate 
in protein-protein interactions (Supplementary figure 3). In addition, structurally and 
functionally important regions in proteins typically appear as patches of evolutionarily 
conserved residues that are spatially close to each other29. To assess the effect of 
missense RP2 mutations on the RP2-OSTF1 interaction, we expressed V5-tagged 
wild-type and mutant forms of RP2 in HEK293T cells and used the lysates for 
pulldown assays using GST-OSTF1 as bait. All the mutations generated were not 
predicted to affect the overall stability of the protein (Supplementary table 2) and 
were, indeed, expressed at wild-type levels. As an additional control to ensure that 
the absence of RP2 in the pulldown samples is specifically due to the loss of the 
RP2-OSTF1 interaction and not an unspecific effect of destabilized secondary 
structure or folding, we conducted pulldown assays using GST-ARL3 Q71L as bait 
and confirmed that none of the mutations impaired the RP2-ARL3 interaction, as was 
predicted. Using this approach, we identified three more residues whose substitution 
severely impacts on the RP2-OSTF1 interaction: Y245, D255 and K160 (Figure 4c). 
While the K160A substitution which abolishes the positive charge has a mild impact 
























severely impairs the interaction. This confirms an important role for K160 on the 
interaction interface. Moreover, we have noted that substituting K252 also affects the 
RP2-OSTF1 interaction, albeit to a lesser extent.  
Sequence conservation and variation was mapped on the surface of RP2 showing 
two highly conserved clusters of residues on the RP2 surface, one that forms the 
ARL3 binding site within the N-terminal β-helix domain and a second cluster located 
on the opposite face of the molecule that spans both the β-helix domain and the C-
terminal NDPK-like domain (Figure 4d). Residues Y245, D255 and K160 were 
localized to this second conserved cluster. Therefore, it is likely that this area forms 
the interaction interface with OSTF1.  Since all identified residues are strictly 
conserved among vertebrates (Figure 4d), we suggest that the interaction occurs 
widely among vertebrates and thus has an important function that merits further 
examination. 
Based on the characterisation of the RP2-OSTF1 interaction presented here, and the 
known structures of both proteins, we used a macromolecular docking strategy in 
order to build a 3D model of the RP2-OSTF1 complex. Although our experiments do 
not tell us the specific interacting OSTF1 residues, they do reveal that both the N- 
and C-terminal domains participate in the interaction. Thus, we performed a series of 
docking calculations whereby the interaction was centred around different residues 
on the surface of OSTF1, and then evaluated models for their compatibility with the 
mutagenesis data (see Methods). Although there were multiple models compatible 
with the experimental data, we observed a single dominant cluster of structural 
similar models (Figure 5). Moreover, the binding surface on OSTF1 for this dominant 
cluster was highly conserved, whereas all other compatible docking models involved 
poorly conserved regions of the OSTF1 surface (Supplementary Figure 4), thus 
strongly suggesting that this model is reflective of the actual complex.  
RP2 recruits OSTF1 to the plasma membrane and regulates cell motility 
A function that has been previously attributed to OSTF1 in cancer cell lines is the 
regulation of cell motility. In particular, OSTF1 negatively regulates cell motility in an 
ERK1/2 pathway-dependent manner via the regulation of the intracellular localization 
of Myo1E, with whom it directly interacts25,26. In order to test if RP2 also has a role in 
























RP2 null cell lines using immortalized human retinal pigment epithelial cells (hTERT-
RPE1). hTERT-RPE1 cells were chosen because they are motile in cell culture, have 
a stable diploid karyotype and are of retinal origin. Two clones (G,I) have distinct 2bp 
deletions in exon 2 which lead to complete absence of RP2 expression (Figure 6a). 
Comparison of the motility of parental RPE1 cells and RP2 null clones demonstrated 
that cells that lack RP2 expression are less motile in both wound healing and 
random migration assays (Figure 6 b,c). Live cell imaging of individual cells in the 
random migration assay revealed a lack of directionality in their movement and the 
inability to form proper lamellipodia-like extensions (Figure 6c). Since OSTF1 was 
previously identified as regulating cell motility, we asked if RP2 regulates OSTF1 
expression, especially since its target ARL3 was recently identified as an activator of 
STAT3 transcription factor21. However, this appears not to be the case as OSTF1 
protein expression remained unchanged in all control and RP2 knockout cells 
(Figure 6a).  
To examine if RP2 exerts a positive impact on cell motility by modulating OSTF1 
localization, biochemical fractionation was performed in HEK293T cells. This showed 
that overexpression of RP2 causes translocation of a pool of endogenous OSTF1 
from the cytoplasm to the membrane fraction (Figure 7a). Similarly, by 
immunofluorescence, overexpression of RP2-EmGFP in HeLa cells leads to the 
recruitment of V5-OSTF1 to the cell membrane, where they co-localize (Figure 7b). 
On the contrary, overexpression of the RP2 G2A pathogenic mutant, which does not 
display the plasma membrane localization of the wild-type protein4, does not recruit 
OSTF1 to the membrane compartment, as shown by subcellular fractionation and 
immunofluorescence (Supplementary figure 5a, b). We hypothesized that by 
recruiting OSTF1 to the membrane, RP2 prevents it from interacting with Myo1E, 
thus promoting cell motility. To test this hypothesis, we used HEK293T cells 
transiently overexpressing FLAG-OSTF1/empty vector or FLAG-OSTF1/RP2-V5 for 
anti-V5 immunoprecipitations and observed that less Myo1E associated with FLAG-
OSTF1 when RP2 was overexpressed (Figure 7c and supplementary figure 6). The 
interaction of Myo1E and OSTF1 has been shown to be disrupted by ERK-mediated 
phosphorylation of OSTF1 S202. Serum stimulation and subsequent ERK activation 




























Studies on the function of RP2 have so far mainly focused on its role in intracellular 
protein trafficking, coordinated via the GAP activity of its N-terminal domain towards 
the small GTPase ARL3. However, the existence of non-canonical roles of RP2 in 
the retina or other tissues has not been fully explored. In addition, the functionality of 
the C-terminal, NDPK-like domain of RP2 has not been elucidated. In order to 
discover novel RP2 functions, we sought to identify novel interaction partners by 
conducting a yeast two-hybrid screen. We identified OSTF1 as a novel direct 
interaction partner and confirmed the interaction by co-IP from HEK293T cells and 
pulldown assays from bovine retinal extracts. Subsequently to our discovery, the 
interaction was recently identified in a large-scale study of the human interactome, 
further validating the interaction30. OSTF1 has been associated with osteoclast 
differentiation23,31 and the regulation of cell motility25,26, but not with retinal 
processes. We investigated the potential relationship of this interaction with the 
ARL3 regulation pathway and found that OSTF1 and ARL3 can simultaneously bind 
on RP2 to create a trimeric complex. These results suggest that OSTF1 does not 
antagonize ARL3 for binding to RP2 and it is unlikely that this newly identified 
partner is a negative or positive regulator of the RP2 GAP activity, at least in vitro. 
Moreover, we screened several non-destabilizing missense RP2 mutations for their 
ability to interact with OSTF1 and found that the R211L mutation entirely abolishes 
the interaction potentially implicating OSTF1 in the pathogenesis of XLRP2. As R211 
is found on a spatially distinct surface of RP2 than the ARL3 interaction interface and 
on a previously uncharacterized RP2 region, this prompted us to follow a site-
directed mutagenesis approach, producing strictly non-destabilizing missense 
mutations, to map the interaction interface, which led to the identification of three 
more residues that are essential for the interaction to occur. The identified residues 
are good candidates for participating in a protein-protein interaction. For example, 
although the surface of RP2 is predominantly negatively charged and, like OSTF1, 
has an acidic theoretical pI, R211 residue belongs to a streak of positively charged 
























charged interactions (Supplementary figure 3). On the other hand, Y245 has an 
exposed aromatic side-chain and belongs to a hydrophobic cluster at the inter-
domain junction of RP2 (Supplementary figure 3). Also, this hydrophobic cluster lies 
within a noticeable surface cavity. Based on our results, we propose that OSTF1 
binds to a cluster of residues on the RP2 surface that are strictly conserved among 
vertebrates and distinct from the ARL3 interaction interface.  This conservation 
analysis hints on an important function of the interaction among vertebrates that is 
most likely distinct from the ARL3 regulation pathways.  
OSTF1 is known to exert a negative effect on cell motility through its direct 
interaction with Myo1E, which leads to Myo1E being “anchored” to the cytoplasm 
and prevents it from translocating to sites of actin nucleation in lamellipodia, an event 
which is essential for their proper formation26. The OSTF1-Myo1E interaction is 
regulated by phosphorylation of OSTF1 by RSK1 under direct control of the ERK1/2 
pathway; activation of ERK and PI3K signaling pathways is long known to be 
required for actin polymerization and subsequent lamellipodium formation32. Here we 
report another way of regulating the negative effect which OSTF1 exerts on cell 
motility: RP2 overexpression results in OSTF1 recruitment to the plasma membrane, 
leading to less OSTF1 being available for interaction with Myo1E. It will be 
interesting to study which signaling pathway activates RP2 to act as an OSTF1 
regulator, an effect that is simulated by RP2 overexpression in our experiments.  
Myo1E is a long-tailed class I myosin which has been suggested to physically 
connect actin to the plasma membrane and thus generate plasma membrane 
tension33. Its deletion in mice leads to defects in kidney filtration34 and it has also 
been associated with poor outcome in breast cancer patients and identified as a 
tumor promoter in a mouse study35. Moreover, Myo1E has a role in coordinating 
actin assembly and trafficking in clathrin-mediated endocytosis36. The potential role 
of RP2 in those processes needs to be clarified further. Interestingly, disruption of 
actin turnover is observed upon knockout of another XLRP gene, RPGR, suggesting 
that actin dysregulation may contribute to the pathology on RP2 patients37. Besides, 
it is important to note that a dynamic organization of the acto-myosin cytoskeleton is 
a prerequisite for most RPE functions in the retina, and many classes of non-muscle 
myosins are implicated in them (e.g., Myosins VIIa, Va in phagocytosis, Myosin II in 
























An important question that arises from our study is whether the RP2-OSTF1 
interaction participates in ciliary traffic and is relevant for RP pathogenesis, or 
whether it has a non-canonical function in a different context/tissue. One hypothesis 
is that there are two distinct RP2 functions, the regulation of ciliary traffic via the 
ARL3 interaction in post-mitotic cells, and the regulation of OSTF1 localization and 
cell motility in dividing cells where cilia are retracted. One the other hand, the two 
functions of RP2 might be related. Interestingly, ARL13B mutant mice show a defect 
in directional migration of interneurons of the cerebral cortex39, while knockdown of 
ARL3 impairs the migrational capacity of HeLa cells21. Future studies should also 
examine whether OSTF1 in its turn affects RP2 localization be preventing its 
localization to the ciliary axoneme.     
Given that R211L is not predicted to destabilize RP2’s folding by in silico analyses17, 
our data suggest that loss of the RP2-OSTF1 interaction may lead to retinal 
degeneration. This could be tested in the future by using CRISPR-mediated genome 
editing to introduce R211L and other mutations that disrupt the RP2-OSTF1 
interaction (such as Y245F) into mice and examining the retinal phenotype. 
Examination of expression data from the Fantom 5 project (http://fantom.gsc.riken.jp) 
shows that OSTF1 is expressed in both embryonic and adult eyes in mice and more 
specifically in both the retina and retinal pigmented epithelia in humans. More 
research will be needed to determine the cellular expression pattern of OSTF1 in the 
retina.  
The RP2 protein has come into the spotlight because of the devastating effect of its 
mutations in the viability of photoreceptors, leading to one of the most early-onset 
and severe forms of RP. However, a multitude of different and often conflicting 
studies point to a multifunctional protein with more than one role in cellular biology40. 
RP2 disease also presents with a distinct set of symptoms that often deviate from 
the classic clinical image that characterises RP patients41. Gene augmentation 
therapy is perhaps the strategy that is closest to the clinic for RP, having already 
proven its safety in LCA patients42. In fact, gene augmentation therapy has already 
successfully prevented degeneration in a mouse RP2 KO model43. However, a 
thorough understanding of protein’s functions are essential and non-canonical 
functions of RP2 must be taken into account, in order to prevent adverse effects and 
























reach the clinic. Our study presents a novel aspect of RP2 function and thus 
contributes to that direction. 
Methods 
Yeast two hybrid 
For the yeast two hybrid screen, the ProQuest™ Two-Hybrid system (Thermo Fisher) 
according to the manufacturer’s instructions. In brief, the full length human RP2 orf 
was cloned into the pDEST32 bait plasmid. This was transformed into S. cerevisiae 
MaV203 yeast cells. These cells were subsequently transformed with the ProQuest™ 
Human Kidney 3-frame cDNA library according to the manufacturer’s instructions. For 
co-transformation assays, the RP2 and OSTF1 orfs were cloned into both the pDEST 
32 bait and pDEST22 prey plasmids. Interaction of bait and prey molecules were 
tested by growth of yeast cells on selective medium containing 75 mM 3-amino 1,2,4,-
triazole but lacking leucine, tryptophan, and histidine and by LacZ-assays with filter-
immobilized cells. 
Generation of RP2 null RPE1 Cells 
Nickase paired guide sequences were identified in exon 2 of human RP2 using the 
Zhang lab CRISPR design tool (crisp.mit.edu). Two paired guide sequences (Guide A 
– tcaaatttggatgttttcaa and Guide B – tttgaggaagactcaatgat) were cloned into pX461 
and pX462 CRISPR plasmids respectively. These plasmids were co-transfected into 
RPE1-hTERT cells and 24 hours later subjected to 24hr selection in 5ug/ml Puromycin 
containing media to select for cells transfected with pX462. After 24hrs selection 
individual GFP-positive cells were FACS-sorted into individual wells of a 96 well plate 
to select for cells transfected with pX461. After expansion, 20 clones were sanger 
sequenced (sequencing primers: ggacccgtgaaaggcagcgtg and 
cctgacacaggtgtaaagtcatgaatgttactcc) and clones harbouring deleterious mutations 
kept together with clones harbouring no mutations as controls. 
Immunofluorescence  
For IF experiments, cells were seeded onto acid etched coverslips and transiently 
transfected. Cells were fixed in 4%PFA/PBS for 10 minutes, washed and then 
























serum (Sigma) in PBS for 1 hour. Primary antibodies were applied in blocking buffer 
for 1 hour at room temperature. Cells were washed in PBS prior to incubation with 
Alexa Fluor®-conjugated goat secondary antibodies (Thermo Fisher) for a further hour 
at room temperature. Finally cells were mounted onto slides using ProLong® Gold 
antifade mountant (Thermo Fisher). Slides were imaged on a Leica SP2 inverted 
confocal microscope. 
Site-directional mutagenesis  
Point mutations were introduced in the human RP2 coding sequence using 
QuikChange II Site-Directed Mutagenesis kit following the manufacturer’s instructions. 
Briefly, pENTR/D-TOPO entry vector (Invitrogen) containing the wild-type human RP2 



















CAGCAATTAGTTT (D255A). Primers for G2A, C3S, R118H, E138G, R211L, R282W 


























To achieve expression of the constructs in mammalian cells, RP2 coding sequences 
were transferred into the destination vector pCDNA-DEST40 (Invitrogen), which 
added an N-terminal V5 tag to the construct, by recombination reaction using LR 
Clonase II (part of the Invitrogen Gateway cloning system).  
Cell culture techniques (motility, transfections, fractionations) 
HEK293T, hTERT-RPE1 and HeLa cells were obtained from the ATCC (American 
type culture collection) and maintained as adherent cultures at 37 oC and 5% CO2. 
HEK293T and HeLa were grown in Dulbecco’s modified Eagle medium (DMEM) with 
4.5g/l L/D glucose and pyruvate (Gibco, Life Technologies), with the addition of 10% 
v/v fetal calf serum and penicillin/streptomycin cocktail at 1 mg/ml final concentration. 
hTERT-RPE1 were grown in DME-F12 medium (Hyclone, Thermo Fisher Scientific) 
with the addition of 10% v/v fetal calf serum, penicillin/streptomycin cocktail at 1 mg/ml 
final concentration and hygromycin (10 μg/ml final concentration). Cells were regularly 
split using the TrypLE trypsin substitute (ThermoFisher Scientific).  All cells were 
routinely tested for contamination by MRC HGU technical services. 
Cells were transiently transfected with 0.5 μg purified plasmid DNA containing the 
relevant constructs (per 0.2x106 cells, using the nonliposomal reagent Fugene HD 
(Promega).  
Cell motility of hTERT-RPE1 cells was assessed by random migration assay and 
scratch wound assay using the Incucyte ZOOM live-cell imaging system (Essen 
Bioscience). For the random migration assay, cells were sparsely plated (1,000 cells 
per well of a 96-well plate), left overnight to adhere and imaged the next day. Distance 
covered by individual cells was analysed blindly using FiJi software. For the scratch 
wound assay, cells were plated in 96-well plates and were subjected to a scratch 
wound when completely confluent (using the WoundMaker tool by Essen Bioscience). 
Density of cells migrating into the wound during the next 24 hours was measured by 


























Cell lysate proteins were separated according to three subcellular fractions 
(cytoplasmic, membrane/organelle and nuclear/cytoskeletal) using a detergent-based 
cell fractionation kit (Cell Signaling technology) according to manufacturer’s 
instructions.  
 
Antibodies used for western blotting, immunoprecipitation 
The following primary antibodies were used for western blotting: mouse monoclonal 
anti-V5, 1: 5,000 (Life technologies R960-25), rabbit polyclonal anti-OSTF1, 1: 10,000 
(Bethyl laboratories A303-004A), mouse monoclonal anti-β actin, 1: 10,000 (Sigma-
Aldrich A3853), rabbit polyclonal anti-RP2, 1: 2,000 (custom-made 7), mouse 
monoclonal anti-histone H3, 1: 1,000 (Abcam ab18521), rabbit polyclonal anti-Integrin 
β1, 1:500 (Millipore AB1952), rabbit monoclonal anti-FLAG, 1:2,000 (Cell Signalling 
#8146), mouse monoclonal anti-c-Cbl, 1:1,000 (BD Bioscience 610441) rabbit 
polyclonal anti-Myc, 1:1,000 (CST 2278) and rabbit monoclonal anti-pERK, 1:1,000 
(CST 4370). 
V5 and FLAG IPs were conducted in triton lysis buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1% Triton-X100). For V5 IPs, 10 μl of anti-V5 agarose affinity gel (Sigma-Aldrich) 
was incubated with 2-3 mg of total cell lysate protein for 1 hr at 4oC under continuous 
rotation. For FLAG IPs, 5 μl of EZ View red anti-FLAG M2 agarose affinity gel (Sigma-
Aldrich) were incubated with 1 mg of total cell lysate protein for 2 hrs at 4oC under 
continuous rotation. After incubation, extensive washes followed to minimize non-
specific protein binding. In the end, immunocomplexes were eluted off the beads by 
adding LDS buffer (NuPage, Life technologies)/DTT and subjected to SDS-PAGE and 
western blotting.  
Plasmids and proteins 
Native full length ARL3 or truncated ARL3 aa 17-177 (ARL3∆N), RP2, RP2 aa 250-
350 (∆N), RP2 aa 35-350 (∆N34) and RP2 mutant R211H were purified as previously 
described to be completely loaded with GppNHp3,16. OSTF1 FL, OSTF1 aa 1-74 
(OSTF∆C) and OSTF1 aa 74-214 (∆N) were cloned into pET20 vector and purified in 
























QIAGEN), a hydrophobic phenyl sepharose column (GE Healthcare) and gel filtration 
using a Superdex 75 16/60 column (GE Healthcare). Buffers were used as previously 
described44,45. The proteins were stored in buffer M containing 25 mM Hepes pH 7.5, 
150 mM NaCl, 5 mM MgCl2, 1 mM DTE and 5% glycerol. 
GST-ARL3 Q71L, GST-OSTF1 and RP2-GST recombinant proteins used in pulldown 
experiments were expressed in BL21 DE3 E.coli cells transformed with pGEX4T3 
vectors (GE Healthcare) containing the relevant constructs. GST-tagged (at the N-
terminal or C-terminal in the case of RP2) recombinant proteins were purified from the 
cell lysate by immobilization on glutathione-sepharose bead slurry (GE Healthcare). 
The protein-bound slurry was stored in PBS containing 10% glycerol and 1 mM DTT.  
 
Pulldown assays 
GST pulldown assays were conducted in mild lysis buffer (25 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1% NP40, 5% glycerol) by incubating 0.7-1 mg of total 
cell lysate or bovine retinal extract protein with ~10 μg of GST-tagged protein bound 
on glutathione-sepharose beads for 2 hrs at 4oC under continuous rotation. The bead-
bound GST protein complexes were washed at least three times in lysis buffer to 
remove non-specifically bound proteins. In the end, GST complexes were eluted off 
the beads by the addition of LDS buffer (NuPage, Life Technologies)/DTT and 
submitted to SDS-PAGE and western blotting.  
 
 
Isothermal Titration Calorimetry (ITC) measurements  
Interactions of RP2 and RP2 R211H with OSTF FL were investigated by isothermal 
calorimetry using an ITC200 microcalorimeter (MicroCal). Measurements were carried 
out in buffer M at 25°C. 585 µM OSTF FL protein in the syringe was injected into the 
cell containing either of 58 µM RP2 or 52 µM RP2 R211H. Analysis of the data was 
performed using the Origin 7.0 Software provided by the manufacturer (MicroCal, LLC 
ITC). 
 
Analytical size exclusion chromatography  
Complex formation of RP2, RP2ΔN or RP2∆N34 with OSTF1 FL, OSTF∆N or 
OSTF∆C was investigated by analytical size exclusion chromatography using a 
Superdex 75 10/300 column (GE Healthcare). A total of 0.5 mg RP2 protein was 
incubated with equal molar amounts of OSTF1 protein for 2 hours at room 
temperature. The mix was then applied to the size exclusion chromatography column 
and eluted with one column volume of buffer M. The elution profile was recorded and 

























Affinity measurements  
ARL3∆N was loaded with mantGDP or mantGppNHp (Pharma Waldhof) overnight at 
12°C by incubation with a 1.5 fold molar excess of nucleotide and purified the following 
day on a desalting column in buffer M16. In case of mantGppNHp alkaline phosphatase 
was added. Nucleotide loading was determined by HPLC measurements on a C18 
column. Polarization data was recorded with a Fluoromax-4 spectrophotometer (Jobin 
Yvon, München, Germany), with excitation and emission wavelengths of mant-
nucleotides at 366 and 450 nm, respectively.  
Qualitative binding and complex formation of OSTF1 FL with ARL3∆N was determined 
by titration of 1 µM ARL3∆N bound to the respective mant-nucleotide with increasing 
amounts of OSTF1 FL. For triple complex formation 1 µM ARL3∆N bound to 
mantGppNHp was supplemented with 10 µM RP2 followed by 20 µM OSTF1 FL or 
buffer, respectively. 
Binding affinities of RP2 to ARL3∆N were measured by monitoring the polarization 
signal during titration of 1 μM ARL3 loaded with mantGppNHp with increasing amounts 
of RP2 in the presence or absence of 10 µM OSTF1 FL at 20°C in buffer M. Obtained 
data points were fitted to a first-order reaction using Grafit5 (Erithacus software) to 
obtain the dissociation constant, Kd. 
The affinity of OSTF1 FL to RP2 was determined indirectly by formation of a complex 
of 1µM ARL3 mantGppNHp with 1µM RP2 which was titrated with increasing amounts 
of OSTF1 FL at 20°C in buffer M. Obtained data points were fitted to a first-order 
reaction using Grafit5 (Erithacus software) to obtain the dissociation constant, Kd. 
 
Measurement of GTP hydrolysis by [-32P]GTP charcoal method 
This was performed as described before16. ARL3 was loaded with GppCH2p with the 
help of bead-linked alkaline phosphatase which was removed via centrifugation and 
another step of gel filtration. Briefly, a mix of 20 µM ARL3-GppCH2p was mixed with 
60 nM [-32P]GTP and 18 µM GTP in Buffer M. Upon a short incubation, the reaction 
was started by addition of 0.2 µM RP2 or 5 µM OSTF1 or a mix of 0.2 µM RP2/5µM 
OSTF1. Aliquots of 10 µl were taken at 10, 20, 40, 60, 90, 120 180, 240 and 300 
seconds and immediately mixed with 400 µl of charcoal solution (50 g*l-1 charcoal in 
20 mM phosphoric acid) to stop the reaction. The charcoal was pelleted and the 
amount of free 32Pi in the supernatant determined by scintillation counting. Data was 
plotted by showing ratio of specific counts per minute (cpm) of supernatant over total 


























Structure-based in silico analyses 
The empirical forcefield FoldX46,47 under the YASARA48,49 molecular visualisation 
program was used to estimate the free energy difference (stability change) upon 
mutagenesis from wild-type as previously described17 
In order to retrieve and select a divergent set of RP2 orthologue sequences for 
multiple sequence alignment, the ConSurf server 50,51 was used with the following 
options (Homologue search algorithm: CSI-BLAST; Number of iterations: 3; E-value 
cut-off: 0.0001; Protein database: UniRef-90; Maximal % identity between 
sequences: 95%; Minimal % identity for homologues: 35%). From the returned 
results, the set of sequences was further manually curated to exclude all ‘fragment’ 
proteins and those proteins that could not be assigned to any genus after cross-
checking their UniRef Accession IDs. Thus, eighteen sequences were finally 
selected and aligned externally using MUSCLE52. The alignment was used as input 
for the ConSurf web server to map sequence conservation on the protein structure of 
RP2. The ‘Bayesian’ method was used to calculate the rate of evolution at each site 
using the ‘JTT’ evolutionary substitution matrix model. The PyMOL Molecular 
Graphics System (Schrödinger, LLC.) was used for visualization, analysis and figure 
preparation. 
The electrostatic surface representation of RP2 was generated by GRASP53 and the 
lipophilic surface rendition was generated using MOLCAD54. 
 
Docking model of the RP2-OSTF1 interaction 
We used the program HADDOCK55 using the standard protein-protein docking 
protocol in order to generate docking models of RP2-OSTF1 dimers from the known 
structures of RP2 (PDB ID: 3BH7) and OSTF1 (PDB ID: 3EHR). The interaction 
surface on RP2 was based on the mutagenesis experiments: the four residues that 
can disrupt the interaction when mutated (Arg211, Lys160, Tyr245 and Asp255) are 
defined as “active” and were constrained to be directly involved in the interface, 
whereas other surface residues within 8 Å of these residues were defined as 
“passive” and were allowed but not strictly constrained to participate in the interface. 
























performed a series of docking runs where the OSTF1 interface was constrained to 
be centred around each of the 121 surface residues (defined as exposing >20 Å of 
solvent-accessible surface area). Surface residues within 3 Å of the central residues 
are defined as core, while other residues within 8 Å are defined as passive. 
Initially, we generated 55 water-refined docking models for each OSTF1 surface 
residue. For each docking model, we used FoldX to predict the effects of each 
experimentally tested mutation on the RP2-OSTF1 interaction. Next, we identified 
docking models that meet the following criteria: i) the interaction involves both the N-
domain (residues 13-73) and C-terminal domain (residues 74-190); ii) the OSTF1 
binding surface does not overlap with the known SH3 binding pocket (residues 21-
24, 26-30, 35, 46-49, 60, 62, 64-65, 68-69); iii) no steric clashes between OSTF1 
and ARL3; and iv) P-value < 0.05 for a Wilcoxon rank-sum test comparison between 
the predicted FoldX effects of the disruptive mutations (R211L, K160A, K160E, 
Y245A, D255A) vs non-disruptive mutations (R118H, E138G, R282W, E205A, 
E206A, K208A, S213A, E215A, R218S, K252A, E256A). For the 73 OSTF1 surface 
residues that had at least one structure compatible with these criteria, we generated 
100 additional docking models. We then further identified docking models that meet 
the above criteria, except they have a P-value < 0.002. For the 53 OSTF1 surface 
residues that had at least one structure compatible with these criteria, we generated 
200 additional docking models. 
Out of the 24555 docking models generated in total, there were 21 that met the 
above criteria, but also had HADDOCK scores < -50, and in which the predicted 
effects of all disruptive mutations are stronger than all non-disruptive mutations. 
These 21 structures were then -mean-
square deviation (RMSD), with all structures in each cluster having <3 Å RMSD with 
all others. 
To assess the evolutionary conservation of OSTF1 interaction surfaces from each 
docking model, we used the residue-specific values calculated by ConSurf29 and 
then calculated the average value for interface-forming residues, normalised by the 
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Figure 1. RP2 directly interacts with OSTF1. a) Schematic showing the main protein 
domains of OSTF1. PR: proline-rich region, SH3: Src-homology 3 domain, ANK: 
ankyrin repeats, AC: acidic amino acid cluster. b) Direct interaction between RP2 
and OSTF1 was identified in a yeast two-hybrid screen and confirmed in two 
directions in a targeted yeast two-hybrid assay. c) Exogenous RP2 and OSTF1 co-
























transfected with plasmids containing RP2-FLAG and/or Myc-OSTF1 were subjected 
to anti-FLAG immunoprecipitation (IP) followed by immunoblotting with anti-Myc or 
anti-FLAG antibodies. d) Bovine retinal extracts were subjected to pull-down assays 
using recombinant GST-RP2 or GST-OSTF1 as bait, followed by immunoblot for 
endogenous OSTF1 or RP2, respectively. Ponceau staining shows the GST-tagged 
proteins. e) Thermodynamic characterisation of the OSTF1-RP2 interaction by 
isothermal titration calorimetry. 0.585 mM His-tagged OSTF1 were injected into 52 


























Figure 2. Binding of OSTF1 on RP2 does not affect the RP2-ARL3 interaction. a,b) 
Complex formation between recombinant OSTF1-His, RP2 and ARL3 (a), as well as 
between recombinant OSTF1-His and ARL3 (b), was monitored on the basis of 
change in fluorescence polarisation signal. The fluorescently-labelled G domain of 
ARL3 was used in the analysis in the following states: mantGppNHp (a non-
hydrolysable GTP analog) -bound ARL3 and mantGDP -bound ARL3. c) Binding to 
























performed with catalytic concentrations of RP2 (GAP) (0.2 μM) and ARL3 (small G 
protein) (20 μM) bound to 60 nM [32P-γ]GTP, in the presence or absence of 5 μM of 
OSTF1. GTP hydrolysis is presented as the ratio of counts at each time-point and 


























Figure 3. The N- terminal domain of RP2 and both the SH3 and ANK domains of 
OSTF1 participate in the interaction. a) Diagram of the deletion constructs of OSTF1-
His and RP2 that were used in the analytical gel filtration and pull-down assays. RP2 
ΔN corresponds to residues 230-350, while OSTF1 ΔN corresponds to residues 75-
214 and OSTF1 ΔC to residues 1-73. b) Analytical gel filtration graphs showing 
complex formation or not between recombinant full-length OSTF1-His and either full-
length RP2 (left) or RP2 ΔΝ (right). c) Analytical gel filtration graphs showing 
complex formation between recombinant full-length RP2 and either OSTF1 ΔΝ (left) 
























interaction with RP2, bovine retinal lysates were subjected to pull-down assays using 
recombinant GST-OSTF1 as bait, either full-length or truncated as indicated, 
followed by immunoblotting for endogenous RP2 and c-Cbl. Ponceau staining shows 

















































Figure 4. a) The RP2-OSTF1 interaction is abolished by the R211L mutation, 
contrary to other missense pathogenic mutations. HEK293T cell lysates previously 
transfected with plasmids containing wild-type RP2-V5 or pathogenic mutant forms 
of the protein were subjected to pull-down assays using recombinant GST-OSTF1 as 
bait. Subsequently, they were subjected to immunoblotting using an antibody to V5 
tag. Ponceau staining shows the presence of the GST-tagged protein. b) Section of 
the multiple sequence alignment of RP2 protein orthologues, encompassing the 
critical OSTF1 interaction position (R211) which is strictly conserved among 
vertebrates. Non-vertebrate chordates and other phyla are shown within the pink 
border. An interesting strictly conserved residue in all species tested is highlighted in 
red (F241 in human RP2). c) Identification of RP2 residues that are critical for the 
RP2-OSTF1 interaction to occur. HEK293T cell lysates previously transfected with 
plasmids containing wild-type RP2-V5 or the same protein encompassing non-
destabilizing missense mutations were subjected to pull-down assays using 
recombinant GST-OSTF1 or GST-ARL3 Q71L as bait. ARL3 Q71L mutant is 
defective in GTP hydrolysis and thus can bind RP2 stably. They were then analysed 
by immunoblotting using an antibody to V5 tag. Ponceau staining shows the 
presence of the GST-tagged protein. d) The ARL3 binding area on RP2, as well as 
the residues that we identified as important for the RP2-OSTF1 interaction 
(highlighted in red), belong to distinct strictly conserved clusters. The RP2-ARL3 
complex crystal structure (PDB ID: 3BH7) is shown in four views rotated by 90o 
about the y-axis with the ConSurf 50,51analysis. RP2 is shown in surface 
representation, where residues are color-coded according to their conservation 
grade in vertebrates, with turquoise-through-maroon indicating variable to strictly 
conserved. Light yellow colour represents positions for which the inferred 
conservation level was assigned with low confidence. ARL3 GTPase is shown in 


























Figure 5.  Docking model of the ternary OSTF-RP2-ARL3 complex compatible with 
experimental mutagenesis data. Shown here is a single structure from Cluster 1 
(Supplementary Figure 4), which comprised approximately half of all docking models 
compatible with the experimental data, and which showed a much more strongly 


























Figure 6. Cells lacking RP2 expression display motility defects a) hTERT-RPE1 cell 
lines were engineered to be RP2 null but express OSTF1 at WT levels. Wild-type 
and RP2 null hTERT-RPE1 cell lysates (G and I clones, x2 biological repeats) were 
subjected to immunoblotting using antibodies for endogenous OSTF1, RP2 and β-
actin as a loading control. b) Wild-type and RP2 null hTERT-RPE1 cells (G and I 
clones) were subjected to a wound healing assay. Images on the left show the state 
























colour represents the wound area, while purple colour at the cell boundaries shows 
the area that has been covered by migrating cells. The graph on the right shows the 
area of the wound that was covered by migrating cells 10 hrs after wound induction 
(mean +/- SEM for 6 technical repeats. p=0.0103 for I vs WT, p<0.0001 for G vs WT 
as calculated by two-tailed unpaired t-tests). c) Random migration of sparsely plated 
individual wild-type and RP2 null hTERT-RPE1 cells (G and I clones) was analysed 
over a 9-hr period. Left panels show representative tracks followed by individual 
cells. The graph on the right shows average distance covered by individual cells 
(n=40 for each cell line) in μm (mean +/- SEM for 4 technical repeats, p<0.0001 for G 
vs WT, p<0.0001 for I vs WT as calculated by two-tailed t-test and two-tailed t-test 


























Figure 7. RP2 overexpression leads to OSTF1 translocation to the membrane 
compartment and dissociation from Myo1E. a) HEK293T cells previously transfected 
with empty plasmid or plasmid containing an RP2-V5 construct were subjected to 
detergent-based subcellular fractionation. The fractions were then analysed by 
immunoblotting using antibodies against V5 tag, endogenous OSTF1, endogenous 
ARL3, endogenous histone H3 (marker for the nuclear fraction), endogenous integrin 
























redistribution of OSTF1 pools to the membrane compartment, it did not affect the 
localisation of ARL3. WCL: whole cell lysate, CF: cytoplasmic fraction, MOF: 
membrane and organelle fraction, CyNF: cytoplasmic and nuclear fraction. b) HeLa 
cells previously transfected with plasmids containing RP2-emGFP and/or V5-OSTF1 
constructs were fixed and subjected to immunofluorescence using an antibody to V5 
tag in order to investigate the localisation of V5-OSTF1. While V5-OSTF1 is cytosolic 
on its own, RP2 overexpression leads to recruitment of V5-OSTF1 to the plasma 
membrane. c) HEK293T cells were transiently transfected with plasmids containing 
different combinations of V5-Myo1E, RP2-V5 and FLAG-OSTF1 constructs. The 
lysates were subjected to anti-FLAG IP to assess how much V5-Myo1E associated 
with FLAG-OSTF1 in the presence or absence of RP2-V5 overexpression, and 
immunoblotting using antibodies to V5 and FLAG tags. d) Stimulation of the ERK1/2 
pathway by serum stimulation slightly stabilizes the RP2-OSTF1 interaction. Cells 
previously transiently transfected with a vector containing an RP2-V5 construct were 
stimulated with 10% fetal bovine serum for the indicated time duration (in minutes) 
following overnight serum deprivation. The lysates were then subjected to anti-V5 
immunoprecipitation and immunoblotting using antibodies to V5 tag, endogenous 


























Supplementary Figure 1. The formation of a tetrameric complex between RP2, 
OSTF1, ARL3 and UNC119a (HRG4) is possible. Complex formation between 
recombinant OSTF1-His, RP2, GST-HRG4 and fluorescently-labelled G domain of 
ARL3-mantGppNHp was monitored on the basis of the change in fluorescence 
polarisation signal. 

























Supplementary Figure 2. The participation of the extreme N-terminus of RP2 is not 
required for the RP2-OSTF1 interaction to occur. Analytical gel filtration graph 
showing complex formation between recombinant full-length OSTF1-His and either 
full-length RP2 or a truncated RP2 protein lacking the first N-terminal 34 residues.  


















































Supplementary figure 3. Lipophilic and electrostatic surface representation of RP2. 
At the top panel, the RP2 crystal structure (PDB ID: 3BH7) is shown in four views 
rotating by 90o about the y-axis of a GRASP 53 electrostatic surface representation. 
Surface charge is color-coded from red (negative) to blue (positive), ranging from -
7.5 kT to +7.5 kT (k=Boltzmann’s constant; T= temperature in Kelvin). At the bottom 
panel, the RP2 crystal structure is shown in four views by 90o about the y-axis of a 
MOLCAD54 lipophilic surface representation, where exposed regions of high 
hydrophobicity are coloured brown and regions of high hydrophilicity are coloured 
blue. The surface representations are in equivalent orientations in the two panels as 
well as in main figure 4d.   

























Supplementary figure 4. Five clusters of docking RP2-OSTF1 docking models. All 21 
RP2-OSTF1 docking models compatible with the experimental data could be split 
into five clusters of conformationally similar models.  (a) Example of one structure 
cluster. The central residues indicate those on OSTF1 for which the docking was 
centred around. (b) Evolutionary conservation scores from ConSurf mapped on the 
surface of OSTF1, with the binding region of each cluster highlighted. Cluster 1 has 
a much more conserved binding surface than any of the others. 

























Supplementary figure 5. Overexpression of the membrane targeting-deficient RP2 
mutant G2A does not lead to recruitment of OSTF1 to the membrane compartment. 
a) HEK293T cells previously transfected with empty plasmid or plasmid containing
an RP2-V5 construct were subjected to detergent-based subcellular fractionation. 
The fractions were then analysed by immunoblotting using antibodies against V5 tag, 
endogenous OSTF1, endogenous histone H3 (marker for the nuclear fraction), 
endogenous integrin β1 (marker for the membrane fraction). Contrary to the wild-
type protein (Figure 7a), RP2 G2A is not enriched in the membrane fraction. 
Moreover, RP2 G2A overexpression does not lead to a redistribution of OSTF1 to 
the membrane fraction. WCL: whole cell lysate, CF: cytoplasmic fraction, MOF: 
membrane and organelle fraction, CyNF: cytoplasmic and nuclear fraction. b) HeLa 
cells previously transfected with plasmids containing RP2 G2A-emGFP and V5-
OSTF1 constructs were fixed and subjected to immunofluorescence using an 
antibody to V5 tag in order to investigate the localisation of V5-OSTF1. Co-
expression of RP2 G2A and OSTF1 does not lead to recruitment of OSTF1 to the 
plasma membrane, as is the case with the wild-type RP2 (Figure 7a).  

























Supplementary figure 6. Full uncropped films corresponding to anti-V5 western 
blotting shown in figure 7c. HEK293T cells were transiently transfected with plasmids 
containing different combinations of V5-Myo1E, RP2-V5 and FLAG-OSTF1 
constructs. The lysates were subjected to anti-FLAG IP to assess how much V5-
Myo1E associated with FLAG-OSTF1 in the presence or absence of RP2-V5 
overexpression, and immunoblotting using an antibody to V5 tag. The bands 
corresponding to V5-Myo1E and RP2-V5 are easily separated due to their 
completely different molecular weights.  

























Supplementary table 1. Equilibrium dissociation constants (Kd) of protein complexes 
(shown in brackets) in the presence or absence of other proteins, determined via 
fluorescence polarization (FP) or isothermal titration calorimetry (ITC).  
Complex Kd (μM) Standard error Method of 
determination 
[1 μM ARL3-
mantGppNHp – RP2] 
0.092 0.077 FP 
[1 μM ARL3-mantGDP-
RP2] 
6.137 1.667 FP 
[1 μΜ ARL3-
mantGppNHp – RP2] + 
OSTF1 (10 μM) 
0.040 0.054 FP 
[1 μM ARL3-mantGDP-
RP2] + OSTF1 (10 μM) 
6.967 1.117 FP 
[1 μM ARL3-
mantGppNHp – RP2] 
+UNC119a (4 μM) 
0.082 0.133 FP 
[RP2-OSTF1] 0.163 0.082 ITC 
[1 μM RP2-OSTF1] + 1 
μM ARL3-
mantGppNHp  
0.672 0.164 FP 
[1 μM RP2-OSTF1] + 1 
μM ARL3-
mantGppNHp +2 μM 
UNC119a 
0.235 0.145 FP 

























Supplementary table 2. Stability analysis of suggested RP2 mutations to probe OSTF1 
interaction. FoldX46,47 is applied to calculate the free energy difference between wild-type 
and mutant. The result is the free energy of mutation (ΔΔG) expressed in Kcal/mol; the 
mean of 10 calculation runs is reported. The error margin of FoldX is ~0.5 Kcal/mol so 
changes in that range are considered insignificant. The prediction decision is based upon 
47,56,57 where: no effect on structural stability: ΔΔG <1.6 Kcal/mol, severely reduced 
structural stability: ΔΔG >1.6 Kcal/mol. Negative values indicate enhanced stabilities. 
Mutation Stability energy calculation on 
human unbound RP2 crystal 
structure (PDB ID: 2BX6) 
[Mean ΔΔG (kcal/mol)] 
Stability energy calculation on human 
RP2-ARL3 crystal structure (PDB ID: 
3BH7) 
[Mean ΔΔG (kcal/mol)] 
K160A 0.31 0.24 
K160E 0.30 0.14 
E205A -0.10 -0.05 
E206A 0.27 -0.09 
K208A -0.34 -0.08 
S213A 0.35 0.72 
E215A 0.15 0.50 
R218S 0.95 0.37 
Y245A 0.48 0.72 
K252A 0.66 0.73 
D255A -0.40 -0.58 
E256A 0.04 -0.01 
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